Owc Pharmaceutical Research Stock EBITDA
| OWCP Stock | USD 0.0001 0.00 0.00% |
OWC Pharmaceutical Research fundamentals help investors to digest information that contributes to OWC Pharmaceutical's financial success or failures. It also enables traders to predict the movement of OWC Pink Sheet. The fundamental analysis module provides a way to measure OWC Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to OWC Pharmaceutical pink sheet.
OWC |
OWC Pharmaceutical Research Company EBITDA Analysis
OWC Pharmaceutical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current OWC Pharmaceutical EBITDA | (10.25 M) |
Most of OWC Pharmaceutical's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, OWC Pharmaceutical Research is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, OWC Pharmaceutical Research reported earnings before interest,tax, depreciation and amortization of (10.25 Million). This is 101.17% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The ebitda for all United States stocks is 100.26% higher than that of the company.
OWC EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses OWC Pharmaceutical's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of OWC Pharmaceutical could also be used in its relative valuation, which is a method of valuing OWC Pharmaceutical by comparing valuation metrics of similar companies.OWC Pharmaceutical is currently under evaluation in ebitda category among its peers.
OWC Fundamentals
| Return On Asset | -0.64 | |||
| Current Valuation | 49.75 K | |||
| Shares Outstanding | 497.5 M | |||
| Shares Owned By Insiders | 11.15 % | |||
| Price To Earning | (12.76) X | |||
| Price To Book | 42.29 X | |||
| EBITDA | (10.25 M) | |||
| Net Income | (10.26 M) | |||
| Cash And Equivalents | 1.47 M | |||
| Cash Per Share | 0.01 X | |||
| Debt To Equity | 0.15 % | |||
| Current Ratio | 3.12 X | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (2.5 M) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | -224.47 | |||
| Market Capitalization | 49.75 K | |||
| Total Asset | 3.55 M | |||
| Retained Earnings | (25.14 M) | |||
| Working Capital | (75 K) | |||
| Current Asset | 112 K | |||
| Current Liabilities | 187 K | |||
| Z Score | -16.4 | |||
| Net Asset | 3.55 M |
About OWC Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze OWC Pharmaceutical Research's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OWC Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OWC Pharmaceutical Research based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with OWC Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OWC Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OWC Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against OWC Pink Sheet
| 0.38 | BKLRF | Berkeley Energy | PairCorr |
| 0.32 | AWCMY | Alumina Limited PK | PairCorr |
| 0.31 | HLN | Haleon plc | PairCorr |
| 0.31 | HLNCF | Haleon plc | PairCorr |
The ability to find closely correlated positions to OWC Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OWC Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OWC Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OWC Pharmaceutical Research to buy it.
The correlation of OWC Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OWC Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OWC Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OWC Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for OWC Pink Sheet Analysis
When running OWC Pharmaceutical's price analysis, check to measure OWC Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OWC Pharmaceutical is operating at the current time. Most of OWC Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of OWC Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OWC Pharmaceutical's price. Additionally, you may evaluate how the addition of OWC Pharmaceutical to your portfolios can decrease your overall portfolio volatility.